Dyne Therapeutics Inc. (DYN)
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 16.00 +0.19%
DYN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.98B
- EPS (TTM)
- -$3.30
- Dividend yield
- None
- 52-week range
- 13.73 – 27.31
- Day range
- 15.25 – 16.12
- Volume / Avg
- 3.49M / 2.76M
- Beta
- —
- Shares outstanding
- 186.75M
- Next earnings
- Nov 4, 2026
52-week range
DYN stock today
Shares of Dyne Therapeutics (DYN) finished higher on Oct 7 at $15.97, a gain of 3.70% or $0.57 per share, versus the S&P 500's 0.22% decline. Shares are 41.5% below their 52-week high of $27.31, set on Aug 12, 2026 and 16.4% above the 52-week low of $13.73, near the bottom of the past year's range. DYN is down 18.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 14.5%.
Dyne Therapeutics has posted a net loss over the last twelve months (EPS of -$3.30), so its P/E ratio is not meaningful. Dyne Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Dyne Therapeutics
Company profileDyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John G. Cox M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 289
- IPO year
- 2020
- Website
- dyne-tx.com
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$36.00+125.42%
- Strong buy 3
- Buy 13
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.88
Dyne Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs DYN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs DYN |
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs DYN |
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs DYN |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs DYN |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs DYN |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs DYN |
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs DYN |
Indexes, lists and sector
Dyne Therapeutics stock FAQ
What is Dyne Therapeutics's stock price today?
DYN last traded at $15.97 as of Oct 7, 4:00 PM EDT, up 3.70% on the day. Prices are delayed at least 15 minutes.
When is Dyne Therapeutics's next earnings date?
Dyne Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.88.
Who is Dyne Therapeutics's CEO?
Mr. John G. Cox M.B.A. is the chief executive officer of Dyne Therapeutics Inc., which has about 289 employees.
What is the DYN 52-week high?
The 52-week high for DYN is $27.31 and the 52-week low is $13.73. The stock is currently 41.5% below its high.